New Mexico Medicaid spending on GLP-1 drugs

How much did New Mexico Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $64.5 million for GLP-1 drugs paid through New Mexico Medicaid in 2025, across at least 64,832 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 113 rows of 255, so these figures are floors.

Pharmacies were reimbursed at least $16.6 million for GLP-1 drugs paid through New Mexico Medicaid in 2026 (quarter 1 only, as posted so far), across at least 16,659 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 31 rows of 73, so these figures are floors.

By year and ingredient

2020at least $587,830No dataat least $3,801,071at least $13,359,241at least $21,727SuppressedSuppressedat least $17,769,868
2021at least $2,353,960No dataat least $2,101,178at least $16,843,558at least $92,590SuppressedSuppressedat least $21,391,288
2022at least $7,250,040at least $55,407at least $1,708,150at least $23,246,219at least $42,763SuppressedSuppressedat least $32,302,579
2023at least $15,246,579at least $761,489at least $1,384,571at least $28,989,331SuppressedSuppressedSuppressedat least $46,381,971
2024at least $29,838,729at least $8,453,862at least $424,677at least $18,769,776at least $9,214SuppressedSuppressedat least $57,496,257
2025at least $39,159,455at least $19,754,764at least $385,114at least $5,200,044SuppressedSuppressedSuppressedat least $64,499,377
2026 (Q1)at least $8,932,094at least $6,522,946at least $57,715$1,055,210No dataSuppressedSuppressedat least $16,567,965

By product, 2025

Ozempicat least $38,760,953at least 39,1382 of 26
Rybelsusat least $291,882at least 27512 of 24
Wegovyat least $106,620at least 10832 of 37
Mounjaroat least $19,742,401at least 18,9099 of 57
Zepboundat least $12,363at least 1217 of 18
Liraglutide (generic name listing)at least $385,114at least 90412 of 36
VictozaSuppressedSuppressed10 of 10
Trulicityat least $5,200,044at least 5,4866 of 34
BydureonSuppressedSuppressed2 of 2
SoliquaSuppressedSuppressed7 of 7
XultophySuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $15,746,586at least 15,88228 of 67
Q2 2025at least $16,450,036at least 16,46029 of 62
Q3 2025at least $16,806,714at least 16,74327 of 61
Q4 2025at least $15,496,041at least 15,74729 of 65

By quarter, 2026 (posted so far)

Q1 2026at least $16,567,965at least 16,65931 of 73

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.